Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for SNDX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 15.10M
March 31, 2026 41.62M
December 31, 2025 64.63M
September 30, 2025 115.43M
June 30, 2025 157.42M
March 31, 2025 215.06M
December 31, 2024 288.12M
September 30, 2024 366.43M
June 30, 2024 434.34M
March 31, 2024 491.89M
December 31, 2023 554.20M
September 30, 2023 359.19M
June 30, 2023 400.04M
March 31, 2023 435.50M
December 31, 2022 467.45M
September 30, 2022 338.10M
June 30, 2022 361.94M
March 31, 2022 374.55M
December 31, 2021 408.37M
September 30, 2021 199.00M
June 30, 2021 214.56M
March 31, 2021 228.20M
December 31, 2020 252.19M
September 30, 2020 131.98M
June 30, 2020 147.65M
Date Value
March 31, 2020 53.51M
December 31, 2019 31.60M
September 30, 2019 44.04M
June 30, 2019 55.28M
March 31, 2019 68.63M
December 31, 2018 53.05M
September 30, 2018 64.27M
June 30, 2018 70.35M
March 31, 2018 86.95M
December 31, 2017 104.32M
September 30, 2017 96.71M
June 30, 2017 109.34M
March 31, 2017 72.62M
December 31, 2016 84.14M
September 30, 2016 93.83M
June 30, 2016 106.24M
March 31, 2016 113.85M
December 31, 2015
September 30, 2015
June 30, 2015
March 31, 2015
December 31, 2014
September 30, 2014 -2.578M
June 30, 2014 4.31M
March 31, 2014 8.433M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
Viking Therapeutics, Inc. 408.32M
Kura Oncology, Inc. 48.43M
ACADIA Pharmaceuticals, Inc. 1.307B
Alnylam Pharmaceuticals, Inc. 1.354B
Anika Therapeutics, Inc. 137.28M

Shareholders Equity (Quarterly) Related Metrics